Clinica Chimica Acta最新文献_第3页

Inflammatory markers in acute ischemic stroke

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-08 DOI: 10.1016/j.cca.2025.120185

Zi-Jie Cao, Qian-Xuan Wang, Yi Sun, Jie Li, Feng-Ling Li

Acute ischemic stroke (AIS) is associated with a high incidence and significant rates of disability, making it a critical focus of clinical research. The current review investigates the role of serum inflammatory markers in the pathogenesis and prognosis of AIS. By quantitatively analyzing specific inflammatory markers, this study aims to enhance the understanding of the pathophysiological mechanisms underlying AIS, support early diagnosis, improve disease assessment, and establish a scientific foundation for targeted treatment strategies to optimize clinical outcomes. From a pathophysiological perspective, multiple inflammatory markers are involved in the inflammatory response that occurs within brain tissue following cerebral ischemia. The serum levels of various inflammatory markers were measured in individuals with AIS, revealing strong correlations between these markers and disease severity. The findings indicate that these markers can serve as reliable indicators of disease progression. Further analysis demonstrated their prognostic value in predicting functional recovery and the risk of recurrence. Notably, during a 3-month follow-up, each 0.32 ng/mL increase in matrix metalloproteinases-9 levels was associated with a 16 % increase in the risk of disability and mortality after AIS. The findings of this review contribute to a more comprehensive understanding of the pathological and physiological mechanisms of AIS and offer a foundation for advancing early diagnostic methods, disease assessment tools, and personalized treatment strategies. Monitoring inflammatory marker levels may enable clinicians to more accurately evaluate disease severity and develop tailored therapeutic interventions, potentially reducing disability and recurrence rates while improving quality of life for individuals with AIS. The findings highlight the potential of precision medicine approaches based on inflammatory markers to shape future AIS treatment paradigms.

{"title":"Inflammatory markers in acute ischemic stroke","authors":"Zi-Jie Cao, Qian-Xuan Wang, Yi Sun, Jie Li, Feng-Ling Li","doi":"10.1016/j.cca.2025.120185","DOIUrl":"10.1016/j.cca.2025.120185","url":null,"abstract":"<div><div>Acute ischemic stroke (AIS) is associated with a high incidence and significant rates of disability, making it a critical focus of clinical research. The current review investigates the role of serum inflammatory markers in the pathogenesis and prognosis of AIS. By quantitatively analyzing specific inflammatory markers, this study aims to enhance the understanding of the pathophysiological mechanisms underlying AIS, support early diagnosis, improve disease assessment, and establish a scientific foundation for targeted treatment strategies to optimize clinical outcomes. From a pathophysiological perspective, multiple inflammatory markers are involved in the inflammatory response that occurs within brain tissue following cerebral ischemia. The serum levels of various inflammatory markers were measured in individuals with AIS, revealing strong correlations between these markers and disease severity. The findings indicate that these markers can serve as reliable indicators of disease progression. Further analysis demonstrated their prognostic value in predicting functional recovery and the risk of recurrence. Notably, during a 3-month follow-up, each 0.32 ng/mL increase in matrix metalloproteinases-9 levels was associated with a 16 % increase in the risk of disability and mortality after AIS. The findings of this review contribute to a more comprehensive understanding of the pathological and physiological mechanisms of AIS and offer a foundation for advancing early diagnostic methods, disease assessment tools, and personalized treatment strategies. Monitoring inflammatory marker levels may enable clinicians to more accurately evaluate disease severity and develop tailored therapeutic interventions, potentially reducing disability and recurrence rates while improving quality of life for individuals with AIS. The findings highlight the potential of precision medicine approaches based on inflammatory markers to shape future AIS treatment paradigms.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120185"},"PeriodicalIF":3.2,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular detection of Strongyloides stercoralis: Emerging factors and diagnostic utility

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-07 DOI: 10.1016/j.cca.2025.120184

Dinie Adila Zainol, Anizah Rahumatullah, Nor Suhada Anuar, Susin Raaj

Strongyloides stercoralis infection, a neglected tropical disease, poses a significant public health threat, especially in immunocompromised individuals. This parasitic nematode can establish chronic infections, potentially progressing to life-threatening conditions such as hyperinfection syndrome and disseminated disease. Timely and accurate diagnosis is critical for effective treatment and the prevention of severe complications. Traditional diagnostic methods, such as stool microscopy, are limited by low sensitivity, particularly for detecting low-intensity infections. Advances in molecular diagnostics, particularly Polymerase Chain Reaction (PCR), have significantly improved sensitivity and specificity, marking a pivotal shift in detection capabilities. However, critical barriers persist, including inconsistencies in sample collection and handling, geographic variations in parasite strains, and the impact of genetic diversity on assay performance. Emerging molecular technologies, such as real-time PCR, loop-mediated isothermal amplification (LAMP), and droplet digital PCR (ddPCR) hold significant promise for further enhancing diagnostic precision. These advanced methods provide opportunities for more robust and accessible diagnostics, particularly in resource-limited settings. To maximize their potential, it is imperative to address existing challenges through the standardization of protocols, optimization of sample handling procedures, and the development of high-quality, reliable reagents. By overcoming these obstacles, molecular diagnostics can be more effectively integrated into clinical and public health frameworks, facilitating improved management and control of S. stercoralis infection, ultimately reducing the morbidity and mitigating the global burden of this neglected tropical disease.

{"title":"Molecular detection of Strongyloides stercoralis: Emerging factors and diagnostic utility","authors":"Dinie Adila Zainol, Anizah Rahumatullah, Nor Suhada Anuar, Susin Raaj","doi":"10.1016/j.cca.2025.120184","DOIUrl":"10.1016/j.cca.2025.120184","url":null,"abstract":"<div><div><em>Strongyloides stercoralis</em> infection, a neglected tropical disease, poses a significant public health threat, especially in immunocompromised individuals. This parasitic nematode can establish chronic infections, potentially progressing to life-threatening conditions such as hyperinfection syndrome and disseminated disease. Timely and accurate diagnosis is critical for effective treatment and the prevention of severe complications. Traditional diagnostic methods, such as stool microscopy, are limited by low sensitivity, particularly for detecting low-intensity infections. Advances in molecular diagnostics, particularly Polymerase Chain Reaction (PCR), have significantly improved sensitivity and specificity, marking a pivotal shift in detection capabilities. However, critical barriers persist, including inconsistencies in sample collection and handling, geographic variations in parasite strains, and the impact of genetic diversity on assay performance. Emerging molecular technologies, such as real-time PCR, loop-mediated isothermal amplification (LAMP), and droplet digital PCR (ddPCR) hold significant promise for further enhancing diagnostic precision. These advanced methods provide opportunities for more robust and accessible diagnostics, particularly in resource-limited settings. To maximize their potential, it is imperative to address existing challenges through the standardization of protocols, optimization of sample handling procedures, and the development of high-quality, reliable reagents. By overcoming these obstacles, molecular diagnostics can be more effectively integrated into clinical and public health frameworks, facilitating improved management and control of <em>S. stercoralis</em> infection, ultimately reducing the morbidity and mitigating the global burden of this neglected tropical disease.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120184"},"PeriodicalIF":3.2,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of serum phosphatidylinositol glycan anchor biosynthesis class U protein as diagnostic biomarker for breast cancer

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-06 DOI: 10.1016/j.cca.2025.120183

Shuo An, Feifei Liu, Yue Shi

Background

Finding markers of breast cancer that are strong specificity and high.

Sensitivity is important. The expression of phosphatidylinositol U（PIGU） protein is increased in a variety of tumor cells, but the role of its secreted fragment in breast cancer is lacking. Methods: Differential expression analysis was performed in breast cancer patients by bioinformatics method. Univariate survival analysis and ROC curve plotting were used to explore the correlation between serum PIGU and the prognosis of breast cancer patients. ELISA was used to detect serum PIGU level. Electrochemiluminescence immunoassay was used to determine serum carcinoembryonic antigen (CEA), carbohydrate antigen-153(CA153) and carbohydrate antigen-125 (CA125) levels. Results: The expression level of PIGU protein in breast cancer tumor tissues was higher than that in normal tissues, and PIGU expression level was a prognostic risk factor for breast cancer patients (HR > 1, p < 0.05) and had good predictive power (AUC = 0.8941). Compared with healthy individuals, the serum PIGU level of breast cancer patients was significantly highly expressed (p < 0.01), and the serum PIGU expression level was weakly positively correlated with CEA (r = 0.3270), but not significantly correlated with CA153 and CA125 (p > 0.05). Conclusion: PIGU has the potential to be a predictive prognostic marker for breast cancer.

{"title":"Identification of serum phosphatidylinositol glycan anchor biosynthesis class U protein as diagnostic biomarker for breast cancer","authors":"Shuo An, Feifei Liu, Yue Shi","doi":"10.1016/j.cca.2025.120183","DOIUrl":"10.1016/j.cca.2025.120183","url":null,"abstract":"<div><h3><em>Background</em></h3><div>Finding markers of breast cancer that are strong specificity and high.</div><div>Sensitivity is important. The expression of phosphatidylinositol U（PIGU） protein is increased in a variety of tumor cells, but the role of its secreted fragment in breast cancer is lacking. <strong>Methods</strong><strong>:</strong> Differential expression analysis was performed in breast cancer patients by bioinformatics method. Univariate survival analysis and ROC curve plotting were used to explore the correlation between serum PIGU and the prognosis of breast cancer patients. ELISA was used to detect serum PIGU level. Electrochemiluminescence immunoassay was used to determine serum carcinoembryonic antigen (CEA), carbohydrate antigen-153(CA153) and carbohydrate antigen-125 (CA125) levels. <strong>Results:</strong> The expression level of PIGU protein in breast cancer tumor tissues was higher than that in normal tissues, and PIGU expression level was a prognostic risk factor for breast cancer patients (HR > 1, p < 0.05) and had good predictive power (AUC = 0.8941). Compared with healthy individuals, the serum PIGU level of breast cancer patients was significantly highly expressed (p < 0.01), and the serum PIGU expression level was weakly positively correlated with CEA (r = 0.3270), but not significantly correlated with CA153 and CA125 (p > 0.05). <strong>Conclusion:</strong> PIGU has the potential to be a predictive prognostic marker for breast cancer.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120183"},"PeriodicalIF":3.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143369767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PIWI-interacting RNA biomarkers in gastrointestinal disease

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-05 DOI: 10.1016/j.cca.2025.120182

Xin-Yi Huang , Shu-Xian Chen , Zhen-Yu Wang , Yong-Sheng Lu , Can-Tong Liu , Su-Zuan Chen

Detection and diagnosis of neoplastic and inflammatory gastrointestinal (GI) diseases are typically based on endoscopic and pathologic examination. In GI neoplastic diseases, diagnosis can be delayed due to the expense and invasive nature of this approach. Recently, PIWI-interacting RNAs (piRNAs), a group of small non-coding RNA molecules containing 24–31 nucleotides, have been thought to serve as biomarkers in many disease processes. For example, piRNAs are differentially expressed in GI cancer but their biologic role remains unclear. Using next-generation sequencing and microarray analyses, researchers have suggested that monitoring piRNAs could facilitate diagnosis and prognosis in GI disease. Herein, we reviewed the use of piRNAs in neoplastic, inflammatory, functional, and other diseases of the digestive system, which could shed new light on cancer screening, early detection, and personalized treatment.

引用次数: 0

Predictive biomarkers of pancreatic cancer metastasis: A comprehensive review

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-04 DOI: 10.1016/j.cca.2025.120176

Mengting Chen , Hongsen Liu , Yufei Xiao , Ruijin Liang , Hong Xu , Bo Hong , Yun Qian

This review provides a comprehensive overview of predictive biomarkers associated with metastasis in pancreatic cancer (PC), one of the most aggressive malignancies characterized by late-stage diagnosis and poor prognosis. Metastasis, particularly to the liver, lungs, and lymph nodes, significantly worsens patient outcomes by compromising organ function and promoting disease progression. Reliable biomarkers for predicting and detecting metastasis at early stages are critical for improving survival rates and guiding personalized therapies. This paper highlights both general and specific biomarkers, including genetic mutations, protein expression changes, and carbohydrate tumor markers such as CA19-9. Immunological factors, including PD-L1, inflammatory cytokines, and chemokines, further influence the metastatic process within the tumor microenvironment (TME). Specific biomarkers play pivotal roles in promoting metastasis through mechanisms such as epithelial-to-mesenchymal transition (EMT), tumor microenvironment remodeling, and immune evasion. Emerging markers such as circulating tumor cells (CTCs) and volatile organic compounds (VOCs) offer promising non-invasive tools for metastasis detection and monitoring. This review not only consolidates existing knowledge but also highlights the mechanisms through which specific biomarkers facilitate metastasis. Despite recent progress, challenges such as biomarker standardization, technical variability, and clinical validation remain, and addressing these hurdles is essential for integrating predictive biomarkers into clinical practice. Ultimately, this review contributes to advancing early detection strategies, personalized treatment options, and improved prognosis for PC patients.

{"title":"Predictive biomarkers of pancreatic cancer metastasis: A comprehensive review","authors":"Mengting Chen , Hongsen Liu , Yufei Xiao , Ruijin Liang , Hong Xu , Bo Hong , Yun Qian","doi":"10.1016/j.cca.2025.120176","DOIUrl":"10.1016/j.cca.2025.120176","url":null,"abstract":"<div><div>This review provides a comprehensive overview of predictive biomarkers associated with metastasis in pancreatic cancer (PC), one of the most aggressive malignancies characterized by late-stage diagnosis and poor prognosis. Metastasis, particularly to the liver, lungs, and lymph nodes, significantly worsens patient outcomes by compromising organ function and promoting disease progression. Reliable biomarkers for predicting and detecting metastasis at early stages are critical for improving survival rates and guiding personalized therapies. This paper highlights both general and specific biomarkers, including genetic mutations, protein expression changes, and carbohydrate tumor markers such as CA19-9. Immunological factors, including PD-L1, inflammatory cytokines, and chemokines, further influence the metastatic process within the tumor microenvironment (TME). Specific biomarkers play pivotal roles in promoting metastasis through mechanisms such as epithelial-to-mesenchymal transition (EMT), tumor microenvironment remodeling, and immune evasion. Emerging markers such as circulating tumor cells (CTCs) and volatile organic compounds (VOCs) offer promising non-invasive tools for metastasis detection and monitoring. This review not only consolidates existing knowledge but also highlights the mechanisms through which specific biomarkers facilitate metastasis. Despite recent progress, challenges such as biomarker standardization, technical variability, and clinical validation remain, and addressing these hurdles is essential for integrating predictive biomarkers into clinical practice. Ultimately, this review contributes to advancing early detection strategies, personalized treatment options, and improved prognosis for PC patients.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120176"},"PeriodicalIF":3.2,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing AI for enhanced evidence-based laboratory medicine (EBLM)

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-03 DOI: 10.1016/j.cca.2025.120181

Tahir S. Pillay , Deniz İlhan Topcu , Sedef Yenice

The integration of artificial intelligence (AI) into laboratory medicine, is revolutionizing diagnostic accuracy, operational efficiency, and personalized patient care. AI technologies(machine learning, natural language processing and computer vision) advance evidence-based laboratory medicine (EBLM) by automating and optimizing critical processes(formulating clinical questions, conducting literature searches, appraising evidence, and developing clinical guidelines). These reduce the time for systematic reviews, ensuring consistency in appraisal, and enabling real-time updates to guidelines. AI supports personalized medicine by analyzing large datasets, genetic information and electronic health records (EHRs), to tailor diagnostic and treatment plans to patient profiles. Predictive analytics enhance outcomes by leveraging historical data and ongoing monitoring to predict responses and optimize care pathways. Despite the transformative potential, there are challenges. The accuracy, transparency, and explainability of AI algorithms is critical for gaining trust and ensuring ethical deployment. Integration into existing clinical workflows requires collaboration between AI developers and users to ensure seamless user-friendly adoption. Ethical considerations, such as privacy,data security, and algorithmic bias, must also be addressed to mitigate risks and ensure equitable healthcare delivery. Regulatory frameworks, eg. The EU AI Regulation, emphasize transparency, data governance, and human oversight, particularly for high-risk AI systems. The economic and operational benefits are cost savings, improved diagnostic precision, and enhanced patient outcomes. Future trends (federated learning and self-supervised learning), will enhance the scalability and applicability of AI in EBLM, paving the way for a new era of precision medicine. AI in EBLM has the potential to transform healthcare delivery, improve patient outcomes, and advance personalized/precision medicine.

{"title":"Harnessing AI for enhanced evidence-based laboratory medicine (EBLM)","authors":"Tahir S. Pillay , Deniz İlhan Topcu , Sedef Yenice","doi":"10.1016/j.cca.2025.120181","DOIUrl":"10.1016/j.cca.2025.120181","url":null,"abstract":"<div><div>The integration of artificial intelligence (AI) into laboratory medicine, is revolutionizing diagnostic accuracy, operational efficiency, and personalized patient care. AI technologies(machine learning, natural language processing and computer vision) advance evidence-based laboratory medicine (EBLM) by automating and optimizing critical processes(formulating clinical questions, conducting literature searches, appraising evidence, and developing clinical guidelines). These reduce the time for systematic reviews, ensuring consistency in appraisal, and enabling real-time updates to guidelines. AI supports personalized medicine by analyzing large datasets, genetic information and electronic health records (EHRs), to tailor diagnostic and treatment plans to patient profiles. Predictive analytics enhance outcomes by leveraging historical data and ongoing monitoring to predict responses and optimize care pathways. Despite the transformative potential, there are challenges. The accuracy, transparency, and explainability of AI algorithms is critical for gaining trust and ensuring ethical deployment. Integration into existing clinical workflows requires collaboration between AI developers and users to ensure seamless user-friendly adoption. Ethical considerations, such as privacy,data security, and algorithmic bias, must also be addressed to mitigate risks and ensure equitable healthcare delivery. Regulatory frameworks, eg. The EU AI Regulation, emphasize transparency, data governance, and human oversight, particularly for high-risk AI systems. The economic and operational benefits are cost savings, improved diagnostic precision, and enhanced patient outcomes. Future trends (federated learning and self-supervised learning), will enhance the scalability and applicability of AI in EBLM, paving the way for a new era of precision medicine. AI in EBLM has the potential to transform healthcare delivery, improve patient outcomes, and advance personalized/precision medicine.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120181"},"PeriodicalIF":3.2,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating levels of PADs and citrullinated histone H3 in SARS-CoV-2 infection: Influence of genetic polymorphisms

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-02 DOI: 10.1016/j.cca.2025.120180

Ilse Adriana Gutiérrez-Pérez , Gloria Pérez-Rubio , José Rafael Villafan-Bernal , Ivette Buendía-Roldán , Oscar Zaragoza-García , Leslie Chávez-Galán , Pedro Rosendo-Chalma , Ingrid Fricke-Galindo , Ramcés Falfán-Valencia , Iris Paola Guzmán-Guzmán

Background

Peptidyl arginine deiminases (PADs) and citrullinated H3 histone (H3Cit) play a crucial role in the inflammatory response. These components determine various clinical situations in COVID-2019 associated pneumonia. Single nucleotide polymorphisms (SNPs) in the genes PADI2 and PADI4 may influence the outcome of poorer patient outcomes. We analyze the association of circulating levels NETs biomarkers (PAD2, PAD4, and H3Cit) and the SNPs on PADI2 (rs1005753 and rs2235926) and PADI4 (rs11203366, rs11203367, and rs874881) in hospitalized patients with severe acute respiratory distress syndrome (ARDs) by SARS-CoV-2 pneumonia.

Methods

A cross-sectional study in 160 hospitalized patients with ARDs by SARS-CoV-2 pneumonia. The plasma levels of PAD2, PAD4, and H3Cit were determined by ELISA method. The SNPs were determined by qPCR using TaqMan probes. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of PAD2, PAD4, and H3Cit plasma levels in outcome by ARDs by SARS-CoV-2 pneumonia.

Results

PAD2, PAD4, and H3Cit concentrations were predictors of invasive mechanical ventilation (IMV) requirement and non-survival. PAD2 were associated with non-survival, while PAD4 and H3Cit were associated with requirement IMV. In addition, PAD2 and PAD4 concentrations were related with inflammation markers such as NLR, MLR, dNLR, SII, SIRI, AISI, and NHL. In the carriers of TT genotype of rs1005753 of PADI2 were associated with increased of H3Cit, while, the carriers of GTG/GTG haplotype of PADI4 was related to the presence of increased of PAD4 circulating levels.

Conclusion

SNPs in PADI2 and PADI4 have a significant influence on concentrations of PAD2, PAD4, and H3Cit, which are predictor markers of requirement IMV and non-survival in severe ARDS by SARS-CoV-2 pneumonia.

{"title":"Circulating levels of PADs and citrullinated histone H3 in SARS-CoV-2 infection: Influence of genetic polymorphisms","authors":"Ilse Adriana Gutiérrez-Pérez , Gloria Pérez-Rubio , José Rafael Villafan-Bernal , Ivette Buendía-Roldán , Oscar Zaragoza-García , Leslie Chávez-Galán , Pedro Rosendo-Chalma , Ingrid Fricke-Galindo , Ramcés Falfán-Valencia , Iris Paola Guzmán-Guzmán","doi":"10.1016/j.cca.2025.120180","DOIUrl":"10.1016/j.cca.2025.120180","url":null,"abstract":"<div><h3>Background</h3><div>Peptidyl arginine deiminases (PADs) and citrullinated H3 histone (H3Cit) play a crucial role in the inflammatory response. These components determine various clinical situations in COVID-2019 associated pneumonia. Single nucleotide polymorphisms (SNPs) in the genes <em>PADI2</em> and <em>PADI4</em> may influence the outcome of poorer patient outcomes. We analyze the association of circulating levels NETs biomarkers (PAD2, PAD4, and H3Cit) and the SNPs on <em>PADI2</em> (rs1005753 and rs2235926) and <em>PADI4</em> (rs11203366, rs11203367, and rs874881) in hospitalized patients with severe acute respiratory distress syndrome (ARDs) by SARS-CoV-2 pneumonia.</div></div><div><h3>Methods</h3><div>A cross-sectional study in 160 hospitalized patients with ARDs by SARS-CoV-2 pneumonia. The plasma levels of PAD2, PAD4, and H3Cit were determined by ELISA method. The SNPs were determined by qPCR using TaqMan probes. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of PAD2, PAD4, and H3Cit plasma levels in outcome by ARDs by SARS-CoV-2 pneumonia.</div></div><div><h3>Results</h3><div>PAD2, PAD4, and H3Cit concentrations were predictors of invasive mechanical ventilation (IMV) requirement and non-survival. PAD2 were associated with non-survival, while PAD4 and H3Cit were associated with requirement IMV. In addition, PAD2 and PAD4 concentrations were related with inflammation markers such as NLR, MLR, dNLR, SII, SIRI, AISI, and NHL. In the carriers of TT genotype of rs1005753 of <em>PADI2</em> were associated with increased of H3Cit, while, the carriers of GTG/GTG haplotype of <em>PADI4</em> was related to the presence of increased of PAD4 circulating levels.</div></div><div><h3>Conclusion</h3><div>SNPs in <em>PADI2</em> and <em>PADI4</em> have a significant influence on concentrations of PAD2, PAD4, and H3Cit, which are predictor markers of requirement IMV and non-survival in severe ARDS by SARS-CoV-2 pneumonia.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120180"},"PeriodicalIF":3.2,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143187772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric case of hemoglobin I-high Wycombe variant 儿童血红蛋白I-high Wycombe变异病例。

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120098

Ridwan B Ibrahim , Beverly Vispo , Titilope Fasipe , Sridevi Devaraj

Over 1400 variants of hemoglobin (Hb) have been identified and characterized with phenotypes ranging from clinically silent to severe clinical manifestations in carriers. Different analytical methods have been established to detect Hb variants. Here, we report the first pediatric case of hemoglobin I-High Wycombe [β59(E3) Lys → Glu] variant found in an infant of Mexican-American descent. The patient is thriving and has no clinical complication due to this hemoglobinopathy. In this case, globin chain analysis and peptide mapping by reversed phase high-performance liquid chromatography revealed the presence of hemoglobin I-High Wycombe which can easily be reported incorrectly as beta thalassemia trait.

超过1400种血红蛋白（Hb）变异已被确定并表征，其表型从临床沉默到携带者的严重临床表现不等。已经建立了不同的分析方法来检测Hb变异。在这里，我们报告了首例在墨西哥裔美国婴儿中发现的血红蛋白I-High Wycombe [β59(E3) Lys → Glu]变异的儿科病例。患者身体健康，没有因这种血红蛋白病而引起的临床并发症。在这种情况下，珠蛋白链分析和反相高效液相色谱的肽图谱显示了血红蛋白I-High Wycombe的存在，这很容易被错误地报告为β地中海贫血特征。

引用次数: 0

MicroRNA biosensors for detection of chronic kidney disease 用于慢性肾脏疾病检测的MicroRNA生物传感器。

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2024.120081

Mohammad Reza Balali , Mohammad Taghizadeh , Mehdi Alizadeh , Yousof Karami , Farzaneh Karimi , Seyyed Hossein Khatami , Mortaza Taheri-Anganeh , Sajad Ehtiati , Ahmad Movahedpour , Reza Mahmoudi , Hassan Ghasemi

Chronic kidney disease (CKD) is a prevalent health condition characterized by gradual kidney function loss. Early detection is crucial for the effective management and treatment of CKD. A promising biomarker for various diseases, including chronic kidney disease, is microRNAs (miRNAs), which are becoming increasingly important due to their stability and differential expression in various disease-related states, including CKD. Recent developments in microRNA biosensors have made it possible to detect miRNAs associated with CKD in a sensitive and specific manner. This review article discusses the current state of microRNA biosensors for detecting CKD and highlights their potential applications in clinical settings. Various microRNA biosensors, including electrochemical, optical, and nanomaterial-based sensors, are explored for their ability to detect specific miRNAs linked to CKD progression. The advantages and limitations of these biosensors are evaluated, focusing on factors such as sensitivity, specificity, and ease of use. Overall, microRNA biosensors are promising diagnostic tools for early detection of CKD. However, challenges such as standardizing protocols, validating in large cohorts, and translating to clinical practice remain to be addressed. Future research efforts should aim to overcome these limitations to fully realize the potential of microRNA biosensors in improving the diagnosis and management of CKD.

慢性肾脏疾病（CKD）是一种以肾功能逐渐丧失为特征的普遍健康状况。早期发现对于CKD的有效管理和治疗至关重要。microRNAs （miRNAs）是包括慢性肾脏疾病在内的各种疾病的一个有前景的生物标志物，由于其在各种疾病相关状态（包括CKD）中的稳定性和差异表达，其变得越来越重要。microRNA生物传感器的最新发展使得以敏感和特异性的方式检测与CKD相关的mirna成为可能。这篇综述文章讨论了用于检测CKD的microRNA生物传感器的现状，并强调了它们在临床环境中的潜在应用。各种各样的microRNA生物传感器，包括电化学、光学和纳米材料传感器，都在探索它们检测与CKD进展相关的特定mirna的能力。评估了这些生物传感器的优点和局限性，重点是灵敏度、特异性和易用性等因素。总的来说，microRNA生物传感器是早期检测CKD的有希望的诊断工具。然而，诸如标准化协议、大规模队列验证以及转化为临床实践等挑战仍有待解决。未来的研究应致力于克服这些限制，以充分发挥microRNA生物传感器在改善CKD诊断和管理方面的潜力。

{"title":"MicroRNA biosensors for detection of chronic kidney disease","authors":"Mohammad Reza Balali , Mohammad Taghizadeh , Mehdi Alizadeh , Yousof Karami , Farzaneh Karimi , Seyyed Hossein Khatami , Mortaza Taheri-Anganeh , Sajad Ehtiati , Ahmad Movahedpour , Reza Mahmoudi , Hassan Ghasemi","doi":"10.1016/j.cca.2024.120081","DOIUrl":"10.1016/j.cca.2024.120081","url":null,"abstract":"<div><div>Chronic kidney disease (CKD) is a prevalent health condition characterized by gradual kidney function loss. Early detection is crucial for the effective management and treatment of CKD. A promising biomarker for various diseases, including chronic kidney disease, is microRNAs (miRNAs), which are becoming increasingly important due to their stability and differential expression in various disease-related states, including CKD. Recent developments in microRNA biosensors have made it possible to detect miRNAs associated with CKD in a sensitive and specific manner. This review article discusses the current state of microRNA biosensors for detecting CKD and highlights their potential applications in clinical settings. Various microRNA biosensors, including electrochemical, optical, and nanomaterial-based sensors, are explored for their ability to detect specific miRNAs linked to CKD progression. The advantages and limitations of these biosensors are evaluated, focusing on factors such as sensitivity, specificity, and ease of use. Overall, microRNA biosensors are promising diagnostic tools for early detection of CKD. However, challenges such as standardizing protocols, validating in large cohorts, and translating to clinical practice remain to be addressed. Future research efforts should aim to overcome these limitations to fully realize the potential of microRNA biosensors in improving the diagnosis and management of CKD.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"567 ","pages":"Article 120081"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2025-02-01 DOI: 10.1016/j.cca.2025.120167

Kangjia Xiao , Chengxuan Xie , Yi Zhang , Meihua Kang , Yanchun Wang , Qingtian Li , Wenqian Dong , Hao Wang , Huaxing Wei , Yanping Hu , Baolong Wang , Renquan Lu

Objective

To investigate the clinical value of serum autoantibodies in the screening and diagnosis of gastric cancer.

Materials & methods

A total of 570 gastric cancer patients and 373 controls were enrolled in this study. Enzyme-linked immunosorbent assay (ELISA) was employed to quantitatively detect autoantibodies in the tested serum, and statistic modeling was conducted to analyze their relationships with various clinical and pathological parameters.

Results

The results of autoantibody detection in gastric cancer patients were significantly different from those of the control group. A combination of 7 autoantibodies, including CLDN18, CAGE1, CTAG1A, PBRM1, RASSF7, IMMP2L and COPB1, was selected for modeling (AUC = 0.885). The diagnostic specificity was approximately 0.86 when combined 7-TAAs with Helicobacter pylori, while the positive predictive value was increased to 0.94. The abnormal elevation of different TAAs proteins in gastric cancer patients is related to factors such as disease stage, tumor differentiation degree, and invasion depth.

Conclusion

The determination of serum autoantibody panel has clinical value in screening and prediction of gastric cancer, and can be used as an auxiliary index in clinical diagnosis. The combination of 7-TAAs and Helicobacter pylori can effectively improve the screening specificity and positive predictive value. The detection results of different proteins were related to the stage of disease, the degree of tumor differentiation and the depth of invasion.

{"title":"The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer","authors":"Kangjia Xiao , Chengxuan Xie , Yi Zhang , Meihua Kang , Yanchun Wang , Qingtian Li , Wenqian Dong , Hao Wang , Huaxing Wei , Yanping Hu , Baolong Wang , Renquan Lu","doi":"10.1016/j.cca.2025.120167","DOIUrl":"10.1016/j.cca.2025.120167","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the clinical value of serum autoantibodies in the screening and diagnosis of gastric cancer.</div></div><div><h3>Materials & methods</h3><div>A total of 570 gastric cancer patients and 373 controls were enrolled in this study. Enzyme-linked immunosorbent assay (ELISA) was employed to quantitatively detect autoantibodies in the tested serum, and statistic modeling was conducted to analyze their relationships with various clinical and pathological parameters.</div></div><div><h3>Results</h3><div>The results of autoantibody detection in gastric cancer patients were significantly different from those of the control group. A combination of 7 autoantibodies, including CLDN18, CAGE1, CTAG1A, PBRM1, RASSF7, IMMP2L and COPB1, was selected for modeling (AUC = 0.885). The diagnostic specificity was approximately 0.86 when combined 7-TAAs with Helicobacter pylori, while the positive predictive value was increased to 0.94. The abnormal elevation of different TAAs proteins in gastric cancer patients is related to factors such as disease stage, tumor differentiation degree, and invasion depth.</div></div><div><h3>Conclusion</h3><div>The determination of serum autoantibody panel has clinical value in screening and prediction of gastric cancer, and can be used as an auxiliary index in clinical diagnosis. The combination of 7-TAAs and Helicobacter pylori can effectively improve the screening specificity and positive predictive value. The detection results of different proteins were related to the stage of disease, the degree of tumor differentiation and the depth of invasion.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120167"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0